Increased expression of metallothionein is associated with irinotecan resistance in gastric cancer

Cancer Research

Volumn 64, Issue 14, 2004, Pages 4703-4706

  Chun, Jong Ho ^a   Kim, Hark Kyun ^a   Kim, Eugene ^a   Kim, In Hoo ^a   Kim, Ju Han ^b   Chang, Hee Jin ^a   Choi, Il Ju ^a   Lim, Hyeong Seok ^a   Kim, Il Jin ^b   Kang, Hio Chung ^b   Park, Jae Hyun ^b   Bae, Jae Moon ^a   Park, Jae Gahb ^a  

^a National Cancer Center   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; DNA; IRINOTECAN; METALLOTHIONEIN; METALLOTHIONEIN IX; RNA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DNA MICROARRAY; DNA REPLICATION; FEMALE; GENE OVEREXPRESSION; HUMAN; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; STOMACH DISEASE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; METALLOTHIONEIN; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; STOMACH NEOPLASMS;

EID: 3142708713     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1063     Document Type: Article

References (12)

1. Chun JH, Kim HK, Lee JS, et al. Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy. Jpn J Clin Oncol 2004;34(1):8-13.
2. Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 2002;8:641-61.
3. Sparreboom A, de Bruijn P, de Jonge MJ, et al. Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces. J Chromatogr B Biomed Sci Appl 1998;712(1-2):225-35.
4. Qian C, Idoate M, Bilbao R, et al. Gene transfer and therapy with adenoviral vector in rats with diethylnitrosamine-induced hepatocellular carcinoma. Hum Gene Ther 1997;8(3):349-58.
5. Kay MA, Landen CN, Rothenberg SR, et al. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sci USA 1994;91(6):2353-7.
6. Guichard S, Chatelut E, Lochon I, Bugat R, Mahjoubi M, Canal P. Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice. Cancer Chemother Pharmacol 1998;42:165-70.
7. Slatter JG, Schaaf LJ, Sams JP, et al. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drug Metab Dispos 2000;28:423-33.
8. Majumder S, Ghoshal K, Gronostajski RM, Jacob ST. Downregulation of constitutive and heavy metal-induced metallothionein-I expression by nuclear factor I. Gene Expr 2001;9:203-15.
9. Miyazaki H, Naitoh Y, Nakahashi Y, et al. Induction of metallothionein isoforms in rat hepatoma cells by various anticancer drugs. J Biochem (Tokyo) 1998;124:65-71.
10. Satoh M, Cherian MG, Imura N, Shimizu H. Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis. Cancer Res 1994;54:5255-7.
11. Wang GW, Klein JB, Kang YJ. Metallothionein inhibits doxorubicin-induced mitochondrial cytochrome c release and caspase-3 activation in cardiomyocytes. J Pharmacol Exp Ther 2001;298:461-8.
12. Fan LZ, Cherian MG. Potential role of p53 on metallothionein induction in human epithelial breast cancer cells. Br J Cancer 2002;87:1019-26.